BMJ (Clinical research ed.)|2026|Wise J
PMID: 41760125
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
AIM: This study aims to examine weight-loss history and pre-treatment concerns, and their associations with current functioning and well-being in adults undergoing incretin-based pharmacotherapy for obesity. MATERIALS AND METHODS: This cross-sectiona…
AIMS: Real-world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP-1 receptor agonist (GLP-1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, o…
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weigh…
BACKGROUND: Psoriasis is a chronic inflammatory skin disease often associated with obesity and metabolic dysfunction, which may worsen disease severity. Glucagon-like peptide-1 receptor agonists, such as semaglutide, have shown metabolic and anti-inf…
The rapid expansion of anti-obesity treatments with glucagon-like peptide-1 receptor agonists has redefined weight management. A consistent component of this weight loss, however, involves not only fat mass but also lean body mass, including skeletal…
BACKGROUND: Acanthosis nigricans (AN) is a recognized cutaneous marker of insulin resistance and metabolic syndrome. Despite its clinical significance and associations with various comorbidities, a comprehensive, quantitative overview of the research…
BACKGROUND: Semaglutide is currently being investigated for its effectiveness in metabolic dysfunction-associated steatotic liver disease (MASLD), irrespective of type 2 diabetes mellitus (T2DM) presence, even though its action on hepatic fibrosis is…
Chronic spontaneous urticaria (CSU) is a mast cell-driven disease that affects approximately 1% of the population. Second-generation non-sedating H-antihistamines (H1AH) are considered the first-line treatment; however, a substantial proportion of pa…
INTRODUCTION: Evidence regarding depression and suicidality with glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains inconsistent, particularly in patients with type 2 diabetes mellitus (T2DM) and underlying affective vulnerability. METHODS:…
IMPORTANCE: Individuals with type 2 diabetes (T2D) are at high risk of atherosclerotic cardiovascular disease (ASCVD). In the SOUL randomized clinical trial, once-daily oral semaglutide reduced risk of major adverse cardiovascular (CV) events by 14%…
UNLABELLED: Glucagon-like peptide 1 receptor (GLP-1R) agonists have transformed obesity treatment, but weight loss responses to these drugs vary widely. Elucidating behavioral and metabolic phenotypes throughout GLP-1R agonist treatment could identif…
Long-term high-fat diets (HFD) induce obesity, neuroinflammation, and cognitive decline, increasing Alzheimer's disease (AD) risk. This study explores whether Semaglutide, a GLP-1 receptor agonist, mitigates these effects by modulating microglia via…
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading chronic liver disease on a global scale. With its increasing incidence and advances in research technologies, our understanding of the mechanisms, non-invasive diagnostic s…